Dx&Vx participates in 'CPhI Barcelona 2023' Discussing Global Partnerships
Dx&Vx announced on the 25th that it will participate in the world's largest biopharmaceutical conference 'CPhI Barcelona 2023' to raise awareness in the global market and start discovering overseas market partners in earnest.
More than 50,000 industry officials, including more than 2,000 pharmaceutical companies, new drug development companies, and drug suppliers, will participate in the event, which will be held in Barcelona, Spain from the 24th to the 26th (local time).
Dx&Vx will discuss various business partnerships, including finding global partners to develop new drugs, supplying its products to overseas markets and distributing global items domestically, and licensing in/out to secure Various business partnerships. To this end, a booth was opened in the venue and a new drug pipeline developed on its own, as well as anti-cancer vaccines, oral vaccines, and new anti-cancer antibodies, will accelerate the signing of partnership contracts with overseas partners, focusing on the Evixgen ophthalmic disease pipeline and microbiome-based biohealthcare products scheduled to be released.
In addition, it plans to introduce differentiated joint diagnostic technologies and services using the best genetic analysis technology know-how in Korea and discuss joint development and service provision with global new drug developers. Oxford Backmedics, a related company, is considering various cooperative measures to increase the value of anticancer vaccine pipelines.
Kwon Kyu-chan, CEO of Dx&Vx, said, "We will significantly improve domestic and foreign sales through networks with global pharmaceutical bio companies and find partners for joint development of new drugs and new products," adding, "We will expand global partnerships and establish various cooperative networks for the development of pipelines and microbiome strains such as new antibody drugs under development."
At this event, Dx&Vx will hold one-on-one meetings with global pharmaceutical company Glanmark, a number of new drug developers, CRO and CMO companies, including Abbvie in the U.S., Egis in France, and SIIT in Italy.